In this way, PARP inhibitors used in cancer therapy (Olaparib, Rucaparib, Niraparib, and Talazoparib) as predictive biomarkers of inhibitor sensitivity, are being analyzed in models where PARylation is maintained in a non-physiological way in HR-deficient cancers. The gene discussed is PARP1; the disease is cancer.